Combination of clinicopathological and MRI based radiomics features in predicting homologous recombination repair genes mutations in prostate cancer.

PURPOSE: To develop Homologous Recombination Repair (HRR) Genes mutations prediction models for prostate cancer using MRI radiomics and clinicopathological features.

METHODS

Totally 353 prostate cancer patients (102 with HRR genes mutations) from three centers (center 1: training and internal test cohorts, center 2 and 3: external test cohorts) underwent multiparametric MRI. Each patient's index tumor lesion was delineated on T2-weighted imaging (T2WI), dynamic contrast enhancement (DCE) MRI, diffusion-weighted imaging (DWI), and apparent diffusion coefficient (ADC) images to obtain 428 radiomics features. Features associated with mutations were selected from clinicopathological features using Mann-Whitney U and Logistic regression (LR) test, radiomics features using Least Absolute Shrinkage and Selection Operator. Clinicopathological model was constructed with selected clinicopathological features. Logistic regression (LR), support vector machine (SVM) and linear discriminant analysis (LDA) classifiers were used to construct Radiomics and combined clinicopathological-radiomics models. Predictive efficiencies of models were compared using areas under the receiver operating characteristic curve (AUC).

RESULTS

One clinicopathological and six radiomics features were selected. Radiomics with SVM, LR, LDA and Clinicopathological models achieved AUCs of 0.76, 0.76, 0.76, 0.68 and 0.75, 0.76, 0.67, 0.73 in internal and external test cohort. AUCs of combined clinicopathological-radiomics models with LDA in internal and external test cohort (0.83 and 0.82) were slightly higher than combined models with LR (0.81 and 0.79) and SVM (both 0.80) (P > 0.05), but were significantly higher than radiomics and clinicopathological models in both cohorts (P < 0.05).

CONCLUSION

LDA classifier incorporating radiomics and clinicopathological features predicting could effectively predict HRR genes mutations in prostate cancer.